Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Apr 26 2010

Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent. This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn's disease as a lead indication.

“Our development and manufacturing collaboration extends our strategic partnership with Cytovance as they have demonstrated on time execution of our first antibody for sickle cell disease. We look forward to this continued alliance as we work together towards advancing this important therapy to patients who suffer from Crohn's”

Under the scope of this agreement, Cytovance will spearhead the cell culture process optimization, recovery and purification development, CGMP manufacturing as well as technical and regulatory support to facilitate Selexys' clinical program. Anti-PSGL-1 mAb will be manufactured at Cytovance's 44,000 sq. ft. production facility that was custom-designed for multi-product CGMP manufacturing and meets US and EU regulatory standards.

"Our development and manufacturing collaboration extends our strategic partnership with Cytovance as they have demonstrated on time execution of our first antibody for sickle cell disease. We look forward to this continued alliance as we work together towards advancing this important therapy to patients who suffer from Crohn's," said Scott Rollins, President and CEO, Selexys Pharmaceutical Corporation. "We are pleased that Selexys has once again chosen Cytovance to work in concert as their development and manufacturing partner," said Darren Head, President and CEO of Cytovance Biologics. "This agreement confirms our shared commitment to highlight the biotechnology life science sector in Oklahoma City and is a testament to our clients to provide unsurpassed quality and innovative technical experience to their most important assets."